---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-078887"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-07-17T01:50:00+00:00"
generated_at: "2026-07-17T10:05:27.391968+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics acquires Kira Pharmaceuticals; issues ~9.8M shares and raises $132M PIPE

## Summary
- Jasper issued ~5.2M common shares and ~4.6M convertible preferred shares to Kira shareholders; Kira holders own ~88.73% of pro forma common pre-PIPE.
- Concurrent $132M PIPE from sale of ~4.7M preferred shares (convertible into 61 common each) to new investors; closing expected July 20, 2026.
- Pre-merger Jasper shareholders receive one CVR per share entitling to pro rata share of $30M if FDA issues Priority Review Voucher for briquilimab by Dec 31, 2028.
- Kira subsidiary entered Mirador License Agreement for anti-C5a assets; $12M upfront, up to $458.5M milestones, low-to-mid single-digit royalties.
- Board changes: Vishal Kapoor and Scott Brun resigned; Patrick Crutcher appointed director; Matthew Ros appointed COO.

## SEC filing metadata
- accession: 0001213900-26-078887
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-07-17T01:50:00+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026078887/0001213900-26-078887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026078887/ea0298229-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-078887
- JSON: https://secwatch.observer/filing/0001213900-26-078887.json
- Plain text: https://secwatch.observer/filing/0001213900-26-078887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.